Inhibitory Effect of Nicardipine on hERG Channel |
Chung, Eun-Yong
(Korea Food and Drug Administration)
Cho, Hea-Young (Korea Food and Drug Administration) Cha, Ji-Hun (National Institute of Food and Drug Safety Evaluation) Kwon, Kyoung-Jin (National Institute of Food and Drug Safety Evaluation) Jeon, Seol-Hee (National Institute of Food and Drug Safety Evaluation) Jo, Su-Hyun (Department of Physiology and Institute of Bioscience and Biotechnology, School of Medicine, Kangwon National University) Kim, Eun-Jung (National Institute of Food and Drug Safety Evaluation) Kim, Hye-Soo (Korea Food and Drug Administration) Chung, Hye-Ju (Korea Food and Drug Administration) |
1 | Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., Siegl, P. K., Strang, I., Sullivan, A. T., Wallis, R., Camm, A. J. and Hammond, T. G. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45. DOI |
2 | Roden, D. M. and Spooner, P. M. (1999). Inherited long QT syndromes: a paradigm for understanding arrhythmogenesis. J. Cardiovasc. Electrophysiol. 10, 1664-1683. DOI |
3 | Sanguinetti, M. C., Chen, J., Fernandez, D., Kamiya, K., Mitcheson, J. and Sanchez-Chapula, J. A. (2005). Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs. Novartis Found. Symp. 266, 159-166. DOI |
4 | Singh, B. N., Baky, S. H. and Nademanee, K. (1985). Second generation of calcium antagonists: The search for greater selectivity or versatility. Am. J. Cardiol. 55, 214B-221B. DOI |
5 | Trudeau, M. C., Warmke, J. W., Ganetzky, B. and Robertson, G. A. (1995). hERG, a human inward rectifier in the voltage-gated Pot. channel family. Science 269, 92-95. DOI |
6 | Zhou, Z., Gong, Q., Epstein, M. L. and January, C. T. (1998). HERG channel dysfunction in human long QT syndrome. J. Biol. Chem. 273, 21061-21066. DOI |
7 | Ficker, E., Dennis, A. T., Wang, L. and Brown, A. M. (2003). Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ. Res. 92, e87-100. DOI |
8 | Finlayson, K., Witchel, H. J., McCulloch, J. and Sharkey, J. (2004). Acquired QT interval prolongation and hERG: implications for drug discovery and development. Eur. J. Pharmacol. 500, 129-142. DOI |
9 | Hamill, O. P., Marty, A., Neher, E., Sakmann, B. and Sigworth, F. J. (1981). Improved patch clamp techniques for highresolution current recording from cells and cell-free membrane- patches. Pflugers Arch. 391, 85-100. DOI |
10 | ICH Harmonized Tripartite Guideline. (2000). Safety pharmacology studies for human pharmaceuticals S7A, step 4. |
11 | ICH Harmonized Tripartite Guideline. (2005). The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals S7B, step 4. |
12 | Kuryshev, Y. A., Ficker, E., Wang, L., Hawryluk, P., Dennis, A. T., Wible, B. A., Brown, A. M., Kang, J., Chen, X. L., Sawamura, K., Reynolds, W. and Rampe, D. (2005). Pentamidine- induced long QT syndrome and block of hERG trafficking. J. Pharmacol. Exp. Ther. 312, 316-323. DOI |
13 | Picard, S. and Lacroix, P. (2003). QT interval prolongation and cardiac risk assessment for novel drugs. Curr. Opin. Investig. Drugs 4, 303-308. |
14 | Rashmi, R. S. (2002). The significance of QT interval in drug development. Br. J. Clin. Pharmacol. 54, 188-202. DOI |
15 | Cordes, J. S., Sun, Z., Lloyd, D. B., Bradley, J. A., Opsahl, A. C., Tengowski, M. W., Chen, X. and Zhou, J. (2005). Pentamidine reduces hERG expression to prolong the QT interval. Br. J. Pharmacol. 145, 15-23. DOI |
16 | Redern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., Mackenzie, I., Palethorpe, S., Siegl, P. K., Strang, I., Sullivan, A. T., Wallis, R., Camm, A. J. and Hammond, T. G. (2004). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs : evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45. |
17 | Ajay, J., Tara, D., Yogesh, V., Changcong, C. and Yan, G. X. (2004). Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models. J. Electrocardiol. 37, 7-14. DOI |
18 | Andrew, T. S. and Lewis, B. K. (1995). Status of safety pharmacology in the pharmaceutical industry-1995. Drug Develop. Research 35, 166-172. DOI |
19 | De Ponti, F., Poluzzi, E., Vaccheri, A., Bergman, U., Bjerrum, L., Ferguson, J., Frenz, K. J., McManus, P., Schubert, I., Selke, G., Terzis-Vaslamatzis, G. and Montanaro, N. (2002). Nonantiarrhythmic drugs prolonging the QT interval: considerable use in seven countries. Br. J. Clin. Pharmacol. 54, 171-177. DOI |
20 | Dennis, A., Wang, L., Wan, X. and Ficker, E. (2007). hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem. Soc. Transactions 35, 1060-1063. |
21 | Fermini, B. and Fossa, A. A. (2003). The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Rev. 2, 439-447. DOI |